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Copyright © 2008 JCBN Summary Series studies suggest that enteropathogenic microorganisms play a substantial
role in the clinical initiation and relapses of ulcerative colitis (UC). Mannan-binding lectin
(MBL) is an important constituent of the innate immune system, and deficiency of MBL has
been reported to increase the overall susceptibility of an individual to infectious disease. This
study was aimed to investigate the associations between polymorphisms of the MBL gene and
UC. Recruited in this study were 108 Japanese patients with UC and 144 healthy control
subjects. Polymorphism at codon 54 of exon 1 of the MBL gene was investigated by
polymerase chain reaction based restriction fragment length polymorphism. In general, no
significant difference in MBL polymorphism was found between UC patients and health
controls. However, the frequency of A carriers was significantly higher in the relapsing cases
than controls (Odds ration = 2.19, 95%CI, 1.10–4.34; p = 0.023), and similar tendency was also
found in A/A genotype. In conclusion, the polymorphism at codon 54 of exon 1 of the MBL
gene associated with the susceptibility to the relapsing phenotype of ulcerative colitis. It
suggests that codon 54 A variants of MBL gene may have an increased risk for the flare-ups
of UC.
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Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD), the
primary constituents of inflammatory bowel disease (IBD),
are precipitated by a complex interaction of environmental,
genetic, and immunoregulatory factors [1, 2]. However, the
pathogenesis of IBD is only partially understood. Some
genes are associated with IBD itself, while others increase
the risk of UC or CD are associated with disease phenotypes
[3,  4]. Both UC and CD are characterized by intestinal
inflammation mainly caused by a disturbance in the balance
between cytokines and increased complement (C) activation
[5, 6].
Mannan-binding lectin (MBL) is an important constituent
of the innate immune system and one of the proteins of the
complement system [7]. Research over the past decade indi-
cates that MBL provides a distinct third pathway of comple-
ment activation, and phygiologenetic studies suggest that it
may have been the first such pathway to have evolved [8–
10]. The biological importance of this pathway is also indi-
cated by the clinical phenotypes of the deficiency state. In
many human populations, MBL deficiency is relatively
common and there have been a large number of studies
attempting to link the deficiency state with particular clinical
presentations [11–13]. This study was designed to investi-MBL Polymorphism in Ulcerative Colitis
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gate the association between polymorphisms of the MBL




A total of 108 chronic UC patients (57 male and 51
female, mean age, 39.3 ± 11.6 years) and 144 health control
subjects (85 male and 59 female, mean age, 36.1 ± 13.5
years) were recruited in the study. Blood or colonic mucosal
biopsy samples were obtained from all the subjects in Fujita
Health University Hospital from April to August 2006. The
diagnosis of UC was made on the basis of clinical manifes-
tations, endoscopic findings as well as histopathological
examinations according to the conventional criteria. In-
formed consent was obtained from all subjects after a full
explanation of the project, and the specimen collecting
procedures were approved by the Ethics Committee in Fujita
Health University.
Classification
According to their clinical courses, chronic UC cases
were classified into one episode, relapsing and continuous
phenotypes [14]. UC were also classified as pancolitis or
distal colitis according to the location and extension of the
inflammatory lesions judged by endoscopic findings. More-
over, cases that need continual intravenous or oral steroid
therapy were identified as steroid dependent, and those had
one onset over 6 months or 2 onsets within one year were
defined as refractory cases.
Genotyping for MBL point mutation
Point mutations at codon 54 of exon 1 of the MBL gene
were detected by polymerase chain reaction (PCR) based
restriction fragment length polymorphism [15]. In brief,
PCR was performed using a total of 50 µl of the following
mixture: 200 ng of genomic DNA, 1 unit Taq DNA poly-
merase, 50 pmol of each primer, 200 ng of each dNTP and
1.5 mM Mg2+. The codon 54 of exon 1 of the MBL was
amplified by the primers (5'-ccttccctgagttttcacac-3' and 5'-
atcagtctcctcatatcccc-3') under the following conditions: an
initial denaturation at 95°C for 5 min, followed by 38 cycles
of 95°C for 40 sec, 55°C for 30 sec, and 72°C for 40 sec.
The final extension step was prolonged to 5 min.
The 298 bp PCR product (10 µl) was cleaved by Ban I
(New England Biolabs. Inc., Bevely, MA) in an appropriate
buffer at 37°C for 2 hours, resulting in two fragments of
195 bp and 103 bp for 54G/G, three bands (298 bp, 195 bp
and 103 bp) for 54G/A (heterozygote), and a single band of
298 bp in the case of 54A/A (homozygote).
Statistic evaluation
The data of age was expressed as mean ± SD. Allele and
genotype frequencies were calculated by direct counting.
The allele counts were compared between UC and its
subgroups and health controls by a 2 × 2 table using
Chi-squared test. Furthermore, the strength of association
between allele frequencies and the disease was assessed by
calculating the odds ration (OR) and 95% confidence inter-
vals (CI). Mean ages between 2 groups were compared with
Student’s t test. A probability value of less than 0.05 was
considered statistically significant.
Results
The results of electrophoresis using clinical samples are
shown in Fig. 1. All of the genotypes were clearly identified.
A total of 108 UC patients and 144 health control subjects
were recruited for the study. The characteristics and the
allele frequency of the MBL gene were shown in Table 1.
There were no significant differences in age and sex ratio
between the 2 groups. Polymorphism at codon 54 of exon 1
of the MBL gene was typed in all 252 subjects. The
frequency of MBL genotypes in the control group did not
deviate significantly from the results expected under the
Hardy-Weinberg equilibrium (p =0 . 3 9 ) .
Statistic comparison of genotype frequencies was carried
Fig. 1. Detection of polymorphism at codon 54 of exon 1 of the
MBL gene by the PCR-RFLP assay. The 298 bp PCR
product was cleaved by Ban I at 37°C for 2 hours, result-
ing in two fragments of 195 bp and 103 bp for 54G/G
(lane 1,2,4 and 6), three bands (298 bp, 195 bp and
103 bp) for 54G/A (heterozygote, lane 5 and 7), and a
single band of 298 bp in the case of 54A/A (homozy-
gote, lane 3).
Table 1. Characteristics of the subjects and allelic frequency
HC group UC group
number of sample 144 108
mean age ± SD 
(age of onset)
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out between healthy control group and each subgroup of UC
patients as well as UC overall (Table 2, 3). In general, there
were no significant difference in the frequencies of A/A and
A/G genotypes at codon 54 of exon 1 of the MBL gene
between healthy control group and patients with UC (OR,
2.03; 95%CI, 0.44–9.39; and OR, 1.43; 95%CI, 0.85–2.39,
respectively). However, the frequency of A carriers in the
relapsing cases was significantly higher than that in controls
(OR, 2.19; 95%CI, 1.10–4.34; p = 0.023), and similar
tendency was also found in A/A carrier (p = 0.053). No
significant association was found between the frequencies of
genotypes of the MBL gene with the rest clinical features
such as gender, age, age of the first onset, or extension of
colitis.
Discussion
Heterogeneity of disease susceptibility in humans and
rodents suggest that multiple mechanisms are responsible
for the etiology of IBD. In particular, deficiencies in anti-
inflammatory and immune-suppressive mechanisms play an
important role in the development of the disease [16–18].
Therefore, IBD is thought to result from a dysregulated
interaction between the host immune system and its
commensal microflora [19,  20]. However, it is unknown
how the enteric microflora stimulates the immune system
and how this response is regulated.
MBL is a pattern recognition molecule of the innate
immune system. It belongs to the collectin family of proteins
in which lectin domains are found in association with
collagenous structures [7, 21]. This permits the protein to
Table 2.T he association between MBL gene polymorphism and ulcerative colitis
Genotype (n) A/A vs G/G A carrier vs G/G
G/G G/A A/A OR (95%CI) OR (95%CI)
Overall
HC group (144) 96 45 3 reference reference
UC group (108) 63 41 4 2.30 (0.44–9.39) 1.43 (0.85–2.39)
Male
HC group (85) 54 29 2 reference reference
UC group (57) 35 20 2 1.54 (0.21–11.5) 1.09 (0.55–2.19)
Female
HC group (59) 42 16 1 reference reference
UC group (51) 28 21 2 3.00 (0.26–34.7) 2.03 (0.92–4.46)
Table 3.T he association between MBL polymorphism and phenotype of ulcerative colitis
Note. n, number of samples; A carrier, A/A + A/G.; + ND, no data; *: p = 0.023
Variables (n)
A/A vs G/G A carrier vs G/G
OR (95% CI) OR (95% CI)
HC group (144) reference reference
Age of Onset
20≥(19) ND 1.80 (0.69–4.72)
>20 (89) 2.42 (0.52–12.2) 1.36 (0.79–2.35)
Clinical type
One episode (9) ND 0.89 (0.26–3.13)
Relapsing (44) 4.57 (0.86–24.2) 2.19 (1.10–4.34)*
Continuous (51) 0.97 (0.10–9.65) 1.09 (0.56–2.13)
Extension
Pancolitis (58) 0.91 (0.09–9.08) 1.31 (0.70–2.97)
Distal colitis (50) 3.43 (0.66–17.9) 1.64 (0.86–3.15)
Response to treatment
steroid-dependent (28) ND 1.78 (0.59–3.19)
refractory (38) 2.78 (0.44–17.6) 1.22 (0.58–2.58)MBL Polymorphism in Ulcerative Colitis
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interact with a wide selection of viruses, bacteria, yeasts,
fungi and protozoa decorated with such sugars. Unlike the
other collectins, MBL bound to microbial surfaces is able to
activate the complement system in an antibody and C1-
independent manner [22]. This activation is mediated by
complexes of MBL with MBL-associated serine protease 2
(MASP-2), which specifically cleaves C4 and C2 to create a
C3 convertase. MBL may also interact directly with cell
surface receptors and thereby promote opsonophagocytosis
by a complement-independent pathway [23–25]. Research
over the past decade has shown that MBL plays an important
role in the first hours/days of any primary immune response
to a sugar-decorated pathogen. This provides the host with a
first-line of defense before the adaptive immune system
becomes operative and in humans may be particularly
important between 6 and 18 months of age when the
adaptive system is still immature [26–28]. MBL deficiency
arises primarily from three single nucleotide polymorphisms
in codons 52, 54 and 57 of exon 1 of the MBL-2 gene, which
result in a failure to assemble fully functional multimeric
protein [29, 30]. These polymorphisms are associated with
decreased MBL plasma concentrations and increased
susceptibility to various infectious diseases [31]. If these
MBL polymorphisms could lead to susceptibility to putative
IBD-etiological microbial agents, or could temper the
complement-mediated mucosal damage in IBD, MBL could
function as the link between certain microbial, immuno-
logical and genetic factors in IBD [32, 33].
Results from our study demonstrated that the frequency of
polymorphism at codon 54 of exon 1 of the MBL gene was
significantly higher in the relapsing cases than that in
controls. It indicates that polymorphism of the MBL gene
may be associated with an increased risk for the flare-ups of
UC. The reason for the association between MBL gene poly-
morphism and relapsing of UC is not clear. Recent studies
indicate that enteric pathogens could cause initial onset of
UC and are associated with reactivation of quiescent disease.
Despite their self-limited character, these infections initiate a
cascade of inflammatory events leading to chronic, relapsing
disease in a genetically susceptible host (“hit-and-run”
hypothesis) [34,  35]. Epidemiological and microbiologic
studies also suggest that enteropathogenic microorganisms
play a substantial role in the clinical initiation and relapses
of IBD [36]. Based on these results, we presume that MBL
gene polymorphism may increase susceptibility of an
individual to enteric infection, which induces the relapse of
inflammation in patients with chronic UC.
Rector  et al. first reported that the MBL gene poly-
morphisms had a protective effect against UC but not CD
[37]. Another study suggests that genetic variants of the
MBL gene are associated with immune reactivity to
mannans in CD [5]. We could not replicate the described
association between the MBL allele and UC: It is possible
that the association seen in other studies may be due to
population stratification and different constitutions of
patients, or to the MBL polymorphism being in linkage with
the real disease-causing variant(s).
Conclusions
Overall, the polymorphism at codon 54 of exon 1 of the
MBL gene was not significantly associated with the
susceptibility to UC. However, the frequency of A allele
carriers of this polymorphism was significantly higher in the
relapsing cases than that in controls. It suggests that codon
54 A variants of MBL gene may have an increased risk for
the flare-ups of UC.
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